Compare Mesoblast Limited (MESO) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Sunrun Inc — how do they compare? Mesoblast Limited trades at $16.39 (market cap $2.17B), while Sunrun Inc trades at $11.46 (market cap $2.73B). The key difference: Sunrun Inc is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| MESO | RUN | |
|---|---|---|
Market Cap | $2.17B | $2.73B |
Sector | Technology | Technology |
52-Week High | $20.96 | $21.41 |
52-Week Low | $12.88 | $9.07 |
Enterprise Value | $2.17B | $16.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Sunrun (RUN) trades at $11.44, down 3.46% today, with a bearish technical outlook. The stock shows strong profitability with a 17.88% net income margin and trades at a low P/E of 5.56. Recent news highlights a major partnership with Tesla and Renew Home for a 16-gigawatt virtual power plant, boosting growth prospects. Earnings have consistently beaten estimates, with Q1 2026 EPS of $0.62 versus -$0.05 expected.
The outlook is mixed: analyst consensus is bullish with a $16.27 price target, but cash flow concerns and high debt-to-asset ratio of 70.76% pose risks. The partnership with Tesla offers significant upside in the AI-driven energy demand sector, yet execution and financing challenges remain key hurdles for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
